Amylyx Pharmaceuticals, in collaboration with The ALS Association, ALS Finding a Cure, and the Massachusetts General Hospital, has dosed the first patient in the CENTAUR study, a Phase II clinical trial assessing the efficacy and safety of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS).
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial.
Eli Lilly's migraine drug Lasmiditan has met its primary endpoint in a second phase 3 trial.
Orbsen Therapeutics’ stromal cell immunotherapy, OBRCEL-M has been approved to begin testing in a randomised, double blind, and placebo-controlled clinical trial in Europe to treat diabetic kidney disease.
Generex Biotechnology's subsidiary, Antigen Express has signed a clinical trial collaboration agreement with Merck, via a wholly-owned subsidiary, to assess Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab), in patients with metastatic triple-negative breast cancer.
AstraZeneca’s Imfinzi (durvalumab) in combination with tremelimumab failed to improve progression-free survival (PFS) significantly in a phase 3 trial in previously untreated patients having advanced lung cancer.
An existing Alzheimer’s medication has been found to cut inflammation and insulin resistance in patients with metabolic syndrome, as per new clinical trial results put up by scientists at Northwell Health’s The Feinstein Institute for Medical Research.
Incyte reported that the first patient has been treated in a phase 3 trial dubbed GRAVITAS-301 for the first-line treatment of patients with acute graft-versus-host disease (GVHD).
Tiziana Life Sciences has started enrolling of patients in its phase IIa clinical trial with cyclin-dependent kinases (CDKs) inhibitor milciclib in patients with refractory hepatocellular carcinoma (HCC).
Vertex Pharmaceuticals has reported positive data from Phase 1 and Phase 2 trials of three different triple combination regimens in cystic fibrosis (CF) patients who have one F508del mutation and one minimal function mutation (F508del/Min).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.